MENU
+Compare
ARKG
ETF ticker: BATS
AS OF
Jul 25, 04:59 PM (EDT)
Price
$26.00
Change
-$0.03 (-0.12%)
Net Assets
1.13B

ARKG stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
ARKG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for ARKG with price predictions
Jul 24, 2025

ARKG's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ARKG turned positive on July 23, 2025. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 218 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ARKG moved out of overbought territory on July 07, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Momentum Indicator moved below the 0 level on July 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ARKG as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARKG broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Market Cap

The average market capitalization across the ARK Genomic Revolution ETF ETF is 115.58B. The market cap for tickers in the group ranges from 66.91M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is RPTX at 66.91M.

High and low price notable news

The average weekly price growth across all stocks in the ARK Genomic Revolution ETF ETF was 4%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was -4%. TXG experienced the highest price growth at 16%, while ABSI experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the ARK Genomic Revolution ETF ETF was -16%. For the same stocks of the ETF, the average monthly volume growth was -19% and the average quarterly volume growth was -27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 84
Price Growth Rating: 50
SMR Rating: 88
Profit Risk Rating: 92
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
ARKG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ARK ETF Trust155 West 19th Street, 5th FloorNew York
Phone
212-426-7040
Web
www.ark-funds.com